Budesonide Inhalation Suspension
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
Solicitation_SPE2D224R0005
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
The Defense Logistics Agency (DLA) Troop Support, a federal office responsible for providing logistical support to military and other government entities, issued a solicitation under procurement identifier Solicitation_SPE2D224R0005 for Budesonide Inhalation Suspension. This procurement falls under the North American Industry Classification System (NAICS) code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and is further classified under Product Service Code 6505, indicating a focus on drugs and biologicals.
The primary objective of this solicitation was to acquire Budesonide Inhalation Suspension, a pharmaceutical product commonly used for respiratory therapies. The intended outcome was to ensure a reliable supply of this medication for use by the agency’s supported populations, aligning with DLA Troop Support’s mission to maintain readiness and health through timely access to essential medical supplies.
Key requirements and deliverables for this procurement would have included the provision of Budesonide Inhalation Suspension in accordance with applicable federal standards for pharmaceutical quality, safety, and efficacy. Contractors were expected to demonstrate capabilities in manufacturing, packaging, and delivering the product as specified in the solicitation documents. While the notice does not detail specific quantities, packaging formats, or delivery schedules, these elements are typically outlined in the solicitation attachments.
The solicitation was posted on December 18, 2024, with a response deadline of February 5, 2024. Interested parties were directed to contact Nancy Fernandez ([email protected], 215-737-4955) or Catherine Gilbert ([email protected], 215-737-4778) for further information or clarification regarding the opportunity.
It is important to note that Amendment 0007, attached to the notice, formally cancels the solicitation. As such, no further action is required from potential contractors, and the procurement process for Budesonide Inhalation Suspension under this specific solicitation has been discontinued.
For reference and additional documentation, the notice and its attachments are available on SAM.gov under Opportunity ID 0648dbb56c6d4215ba03065d634bb1c8. Contractors interested in future opportunities of a similar nature are encouraged to monitor DLA Troop Support’s postings and maintain communication with the listed contacts.
In summary, while this procurement sought to secure a critical pharmaceutical product for federal use, the solicitation has been cancelled and will not proceed further. Contractors should take note of the cancellation and look for future solicitations that may align with their capabilities in pharmaceutical manufacturing and supply.
Documents9